Follow-up studies

When warranted, ERBC conducts follow-up and supplemental safety pharmacology studies. These studies allow to investigate the mechanism of adverse effects suspected and/or observed through the core battery or the clinical trials programs and/or to evaluate potential adverse pharmacodynamic effects on organ system functions not addressed by the core battery or repeated dose toxicity studies.

Cardiovascular system

Cardiac output
Ventricular contractility
Vascular resistance
Effects of endogenous or exogenous substances on the cardiovascular responses
…

Respiratory System

Airway resistance
Compliance
Pulmonary arterial pressure
Blood gases and blood pH
…

Central Nervous System

Behavioral pharmacology
Learning and memory
Ligand-specific binding
Neurochemistry
Visual, auditory and/or electrophysiology examinations
…

Autonomic Nervous System

Ligand-specific binding
Functional response to agonists or antagonists
…

Renal/Urinary system

Diuresis, osmolality and pH in rat
Fluid/electrolyte balance in rat
Plasma proteins, cytology and blood chemistry in rat
…

Gastrointestinal system

Gastric secretion in rat
Gastric damage (ulcerogenic potential in mouse)
Gastrointestinal motility (charcoal meal propulsion in mouse)
…

Other Organ Systems

ERBC investigates on a routine basis the effects of new therapies on immune, endocrine and hepatic functions (including the appearance of liver damages).